Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
Read more
06
June 2022
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
Read more
27
May 2022
Enterome to present three abstracts on its novel OncoMimics™ cancer immunotherapies at ASCO 2022
Read more
23
May 2022
Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference
Read more
19
May 2022
Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022
Read more
05
April 2022
Enterome to present the significant potential of its Mimicry concept, platform and pipeline at BMO’s Biopharma Spotlight Series conference – Immunology and Inflammation
Read more
10
November 2021
Enterome to present significant progress with its OncoMimics™ pipeline at Jefferies London Healthcare Conference
Read more
04
October 2021
Enterome to attend upcoming conferences
Read more
16
September 2021
Enterome highlights Microbiome publication describing sibofimloc’s novel mechanism of action for the treatment of Crohn’s disease
